Canntab to Commence Trading on CSE on 4/20

- April 19th, 2018

Canntab Therapeutics Limited (CSE:PILL) (formerly Telferscot Resources Inc.) (“Canntab” or the “Company”) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (the “CSE”) at the opening of the market on Friday, April 20, 2018 under the stock symbol “PILL”.

Canntab Therapeutics Limited (CSE:PILL) (formerly Telferscot Resources Inc.) (“Canntab” or the “Company”) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (the “CSE”) at the opening of the market on Friday, April 20, 2018 under the stock symbol “PILL”.

“We are proud to announce that Canntab has joined the growing family of cannabis companies listed on the CSE, and believe that this represents an important milestone for the Company and our loyal shareholders. Canntab was able to take this step on only the second anniversary from its date of incorporation, and we intend to continue taking steps like these to enhance shareholder value, increase liquidity and execute on our strategic vision,” said Jeff Renwick, CEO and a director of Canntab.

Stock Options

In connection with the CSE listing, the Company also announces that the board of directors has authorized the grant of 430,000 incentive stock options to certain of its directors, officers, employees and consultants. Each such option entitles the holder to acquire one common share for a period of 3 years at an exercise price of $1.00 per common share.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited
Richard Goldstein, CFO
Office: 416 957-6303
info@canntab.ca

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Click here to connect with Canntab Therapeutics (CSE:PILL) for an Investor Presentation. 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

One response to “Canntab to Commence Trading on CSE on 4/20

Leave a Reply

Your email address will not be published. Required fields are marked *